Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04251611
Other study ID # CEIC 18/82
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2019
Est. completion date May 30, 2022

Study information

Verified date June 2022
Source Althaia Xarxa Assistencial Universitària de Manresa
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Main objective: To assess the efficacy of a phase III cardiac rehabilitation program (CRP), based on counseling in the maintenance of physical exercise (time of physical exercise per week) for patients with myocardial ischemia (MI), once the supervised physical exercise program of phase II of CRP is completed. Secondary objectives: To assess the efficacy of a phase III program of CRP based on counseling in the maintenance of physical exercise for the patient with MI in: 1) the energy expenditure per week, 2) body mass index and abdominal perimeter, 3) control of cardiovascular risk factors (smoking, high blood pressure, dyslipidemia and diabetes mellitus), 4) quality of life related to health, 5) assess the adherence to cardiac pharmacological treatment. Method: Randomized clinical trial in conglomerates, open and controlled. The intervention group will carry out phase III of CRP based on counseling in the maintenance of physical exercise. The control group will receive the usual care. The main outcome will be the physical exercise time per week after finish the supervised physical exercise program of phase II of CRP and at 6 and 12 month later according to the 7-day Physical Activity Recall.


Recruitment information / eligibility

Status Completed
Enrollment 101
Est. completion date May 30, 2022
Est. primary completion date May 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients diagnosed with myocardial ischemia, angina pectoris, other specific forms of chronic ischemic heart disease or unspecified ischemic heart disease. - Patients who have completed the supervised physical exercise program of phase II of the CRP. - Absence of cognitive deficit (Pfeiffer test: 0-2 mistakes). - Sufficient functional capacity to follow the CRP (Barthel index >60) - Residence in catchment area of Bages and Moianès. - Providing signed informed consent. Exclusion Criteria: - Symptoms of right heart failure producing pulmonary hypertension. - Dyspnea caused by severe pulmonary pathology. - Additional comorbidities affecting the prognosis of cardiac disease. - Major comorbidities or limitations that could interfere with the exercise training programme.

Study Design


Intervention

Other:
Maintenance of physical exercise
Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.

Locations

Country Name City State
Spain Althaia Xarxa Assistencial Universitària de Manresa Manresa Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Núria Santaularia Capdevila Institut Català de la Salut

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The physical exercise minutes performed by the patient per week The physical exercise minutes performed by the patient per week will be recorded through the 7-day Physical Activity Recall (PAR) questionnaire. At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Primary The physical exercise minutes performed by the patient per week The physical exercise minutes performed by the patient per week will be recorded through the 7-day Physical Activity Recall (PAR) questionnaire. At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Primary The physical exercise minutes performed by the patient per week The physical exercise minutes performed by the patient per week will be recorded through the 7-day Physical Activity Recall (PAR) questionnaire. At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The energy expenditure by the patient per week The energy expenditure by the patient per week will be recorded through the 7-day Physical Activity Recall (PAR) questionnaire. At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The energy expenditure by the patient per week The energy expenditure by the patient per week will be recorded through the 7-day Physical Activity Recall (PAR) questionnaire. At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The energy expenditure by the patient per week The energy expenditure by the patient per week will be recorded through the 7-day Physical Activity Recall (PAR) questionnaire. At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The body mass index (BMI) BMI is the quotient between the weight (kg) and the square of the height (m). It is usually used for the definition of underweight (BMI <15.99), normal weight (BMI 18.5 to 24.99), overweight (BMI = 25 kg / m2) and obesity (BMI = 30 kg / m2). At baseline of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The body mass index (BMI) BMI is the quotient between the weight (kg) and the square of the height (m). It is usually used for the definition of underweight (BMI <15.99), normal weight (BMI 18.5 to 24.99), overweight (BMI = 25 kg / m2) and obesity (BMI = 30 kg / m2). At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The abdominal circumference Abdominal circumference is the measurement of the abdomen of the patient at the level of the navel. It will be recorded in centimeters using a tape measure. At baseline of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The abdominal circumference Abdominal circumference is the measurement of the abdomen of the patient at the level of the navel. It will be recorded in centimeters using a tape measure. At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The control of smoking Smoking:The degree of dependence on tobacco consumption will be recorded through the Fargeström test. At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The control of smoking Smoking:The degree of dependence on tobacco consumption will be recorded through the Fargeström test. At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The control of smoking Smoking:The degree of dependence on tobacco consumption will be recorded through the Fargeström test. At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Systolic blood pressure Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Systolic blood pressure Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Systolic blood pressure Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Diastolic blood pressure Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Diastolic blood pressure Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Diastolic blood pressure Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Total cholesterol Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Total cholesterol Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Total cholesterol Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Low-density lipoproteins cholesterol Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Low-density lipoproteins cholesterol Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Low-density lipoproteins cholesterol Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary High-density lipoproteins cholesterol Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary High-density lipoproteins cholesterol Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary High-density lipoproteins cholesterol Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Triglycerides Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Triglycerides Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Triglycerides Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Basal plasma glucose Physiological parameter At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Basal plasma glucose Physiological parameter At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Basal plasma glucose Physiological parameter At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The quality of life related to health. Level of perception of the patient regarding their state of health. It will be measured through the EuroQol-5D test. At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The quality of life related to health. Level of perception of the patient regarding their state of health. It will be measured through the EuroQol-5D test. At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary The quality of life related to health. Level of perception of the patient regarding their state of health. It will be measured through the EuroQol-5D test. At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Assess the adherence to cardiovascular medication. It will be recorded if the patient is successfully taking the cardiovascular medication through the Haynes-Sackett test. At baseline, when the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Assess the adherence to cardiovascular medication. It will be recorded if the patient is successfully taking the cardiovascular medication through the Haynes-Sackett test. At 6 months of the supervised physical exercise program of phase II of the CRP has been completed.
Secondary Assess the adherence to cardiovascular medication. It will be recorded if the patient is successfully taking the cardiovascular medication through the Haynes-Sackett test. At 12 months of the supervised physical exercise program of phase II of the CRP has been completed.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT02707445 - Genotyping Influences Outcome of Coronary Artery Stenting N/A